Associated tags: Patient, PTC, PTC Therapeutics, Therapy, Pharmaceutical industry
Locations: BELGIUM, UNITED STATES, BOSTON, MA, EUROPE, NEW JERSEY, SG, EU, US
SOUTH PLAINFIELD, N.J., Oct. 16, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, Oct. 26, at 4:30 p.m.
Key Points:
- SOUTH PLAINFIELD, N.J., Oct. 16, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, Oct. 26, at 4:30 p.m.
- To access the call by phone, please click here to register and you will be provided with dial-in details.
- To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call.
- The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations .
Retrieved on:
Friday, September 15, 2023
PTC Therapeutics,
Duchenne muscular dystrophy,
CHMP-FM,
PTC,
European Medicines Agency,
Committee for Medicinal Products for Human Use,
Committee,
EMA,
DMD,
Patient,
STRIDE,
Therapy,
EC,
News,
Disease,
CHMP,
Vaccine,
Dietary supplement,
Ataluren SOUTH PLAINFIELD, N.J., Sept. 15, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The negative opinion also applies to the renewal of the existing conditional authorization. PTC plans to submit a request for re-examination per EMA guidelines. Translarna will remain on the market and available to patients with nmDMD until the re-examination process is completed. Based on CHMP procedural guidance, the opinion following the re-examination process would be expected to occur in January 2024, with EC ratification of the opinion within the following 67 days.
Key Points:
- The negative opinion also applies to the renewal of the existing conditional authorization.
- Based on CHMP procedural guidance, the opinion following the re-examination process would be expected to occur in January 2024, with EC ratification of the opinion within the following 67 days.
- We will be submitting a request for re-examination to the CHMP to reverse this opinion, as we have done previously in the regulatory history of Translarna in Europe."
- Translarna received conditional marketing authorization in Europe in 2014 based on the results of Study 007, and the conditional authorization was renewed in 2017.
Retrieved on:
Tuesday, September 12, 2023
GSK,
Tuck School of Business,
PTC Therapeutics,
Therapy,
Lehman Brothers,
Rice University,
Syneos Health,
Biotechnology,
PTC,
Business,
Human Genome Sciences,
Dartmouth College,
History,
CNS,
Inotek Pharmaceuticals,
Acquisition,
Nature,
Drug discovery,
HGSI,
Economics,
Pharmaceutical industry,
Sensorium BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors.
Key Points:
- BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors.
- “We are excited to welcome David to our Board,” said Dick Simon, Chief Executive Officer of Sensorium.
- “He is a seasoned life sciences executive with a track record of success that spans multiple therapeutic areas and development stages.
- in economics and managerial studies from Rice University and an M.B.A. from the Tuck School of Business at Dartmouth College.
Retrieved on:
Thursday, September 7, 2023
PTC Therapeutics,
CSE,
University,
Disability,
PTC,
Quality of life,
Social,
University of Queensland,
Duchenne muscular dystrophy,
Wheelchair,
Organization,
NASW,
MLA,
Patient,
Transition,
Blue Angels,
Sport,
Health,
Therapy,
Disease,
Pharmaceutical industry,
Nursing,
Duchenne SOUTH PLAINFIELD, N.J., Sept. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the two recipients of its 2023 STRIVE Awards for Duchenne Muscular Dystrophy. Through the STRIVE program, the company awards grants to non-profit patient advocacy organizations serving the Duchenne community. This year's grants will fund projects focused on developing a digital health app to support patients transitioning to adulthood in Australia and the expansion of a power soccer (also known as powerchair football) program in Brazil.
Key Points:
- SOUTH PLAINFIELD, N.J., Sept. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the two recipients of its 2023 STRIVE Awards for Duchenne Muscular Dystrophy.
- Through the STRIVE program, the company awards grants to non-profit patient advocacy organizations serving the Duchenne community.
- "As we near a decade of the STRIVE Awards program, we are proud to continue to provide organizations with support to expand their services for the Duchenne community."
- "It has been such a rewarding experience to be part of the judging panel for the STRIVE Awards Program.
Retrieved on:
Wednesday, August 30, 2023
SOUTH PLAINFIELD, N.J., Aug. 30, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
Key Points:
- SOUTH PLAINFIELD, N.J., Aug. 30, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation.
- It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.
Asymptomatic,
PTC Therapeutics,
SMN2,
Civil service commission,
PTC,
Roche,
Committee for Medicinal Products for Human Use,
Genentech,
Ventilation,
Committee,
European Commission,
Patient,
European,
Therapy,
Disease,
CHMP,
Birth control,
Pharmaceutical industry,
EU,
Risdiplam SOUTH PLAINFIELD, N.J., July 21, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of the Evrysdi® (risdiplam) marketing authorization to include infants under two months of age in the European Union (EU). A final decision regarding the approval is expected from the European Commission later this year.
Key Points:
- A final decision regarding the approval is expected from the European Commission later this year.
- "The CHMP opinion represents another important milestone in the development of Evrysdi," said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics.
- "Presymptomatic babies are an important patient group that deserve access to oral, at-home administered treatments early in the disease."
- Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics.
SOUTH PLAINFIELD, N.J., July 20, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its second quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, Aug. 3, at 4:30 p.m.
Key Points:
- SOUTH PLAINFIELD, N.J., July 20, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its second quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, Aug. 3, at 4:30 p.m.
- To access the call by phone, please click here to register and you will be provided with dial-in details.
- To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call.
- The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations .
PTC Therapeutics,
University,
Ataluren,
Culture,
PTC,
Messenger,
Genetics,
Knowledge,
Dentistry,
Rare,
Therapy,
Management,
Neuroscience SOUTH PLAINFIELD, N.J., July 19, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Allan Jacobson, Ph.D., co-founder of PTC and member of the Board of Directors, was presented the 2023 Gruber Genetics Prize for his work in identifying and describing the mechanism of nonsense-mediated mRNA decay today in a ceremony in Australia.
Key Points:
- SOUTH PLAINFIELD, N.J., July 19, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Allan Jacobson, Ph.D., co-founder of PTC and member of the Board of Directors, was presented the 2023 Gruber Genetics Prize for his work in identifying and describing the mechanism of nonsense-mediated mRNA decay today in a ceremony in Australia.
- "On behalf of PTC's Board of Directors and leadership team we congratulate Allan on receiving this prestigious award and recognition," said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics.
- The Gruber International Prize Program honors individuals in the fields of Cosmology, Genetics and Neuroscience, whose groundbreaking work provides new models that inspire and enable fundamental shifts in knowledge and culture.
- Dr. Jacobson shares the prize with Lynn Maquat, Ph.D., a molecular biologist at the University of Rochester School of Medicine and Dentistry.
Workforce,
LLP,
Employment,
PTC Therapeutics,
Friedreich's ataxia,
PTC,
Research,
Patient,
United,
Pomerantz,
Therapy,
Private investigator NEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT).
Key Points:
- NEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT).
- Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
- The investigation concerns whether PTC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
Ferring Pharmaceuticals,
PTC Therapeutics,
University,
PTC,
Perella Weinberg Partners,
Barclays,
Patient,
ESCP Business School,
CFO,
Knowledge,
Pierre,
Therapy,
Family,
Pharmaceutical industry,
Science SOUTH PLAINFIELD, N.J., July 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Pierre Gravier to the role of Chief Financial Officer (CFO).
Key Points:
- SOUTH PLAINFIELD, N.J., July 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Pierre Gravier to the role of Chief Financial Officer (CFO).
- Mr. Gravier brings more than 17 years of experience as an investment banker, venture capitalist and scientist to PTC.
- Most recently, Pierre was a managing director in the healthcare group of Perella Weinberg Partners, a leading independent global advisory firm.
- "We are incredibly excited to have Pierre as part of PTC's leadership team," said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics.
